Cencora (NYSE:COR) Azioni

Cencora

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

CoreSite Realty

Long Ideas

News

Markets

Media

Trading Ideas

LMND

Il noto analista di Wall Street mette in guardia gli investitori riguardo a un&#39;azione che ha registrato un aumento eccessivo.

Jim Cramer: questo titolo è &#34;salito troppo… Bisogna lasciarlo scendere&#34;

Cencora Inc

Coreto

GLOBAL CORD BLOOD CORP by Global Cord Blood Corporation

Global Cord Blood Corp

CORNWALL RESOURCES INC by Cornwall Resources, Inc.

cVault.finance

Core - United States Dollar

Coreum - United States Dollar

Cordia Corp

CorEnergy Infrastructure Trust Inc Depositary Shares each representing 1/100th of a whole share of Series A Preferred Stock

Teucrium Corn Fund ETV

iShares International Country Rotation Active ETF

Pimco Investment Grade Corporate Bond Index Exchange-Traded Fund

CorEnergy Infrastructure Trust Inc OM

CorEnergy Infrastructure Trust Inc

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc

Volatility Shares Trust 2x Corn ETF

Core Scientific Inc

Core Scientific Inc Ordinary Shares - Class A

Core Scientific, Inc. - Tranche 1 Warrants

Core Scientific, Inc. - Tranche 2 Warrants

Citigroup analyst Michael Rollins maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Buy and raises the price target from $330 to $355.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Cencora, Raises Price Target to $355

Baird analyst David Rodgers maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Outperform and raises the price target from $314 to $350.

Baird Maintains Outperform on Cencora, Raises Price Target to $350

Cencora, Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $75.68 billion</a>, primarily due to an 11.4% increase in revenue within the U.S. Healthcare Solutions segment.
U.S. Healthcare Solutions revenue was $68.3 billion, due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class and specialty products to physician practices and health systems.
The company reported adjusted EPS of $4.42, up 16.3% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45247410/cencora-reports-fiscal-2025-second-quarter-results" rel="noreferrer noopener">consensus of $4.11</a>.
Adjusted gross profit in the second quarter of fiscal 2025 was $2.9 billion, a 15.2% year-over-year increase, due to the increase in gross profit in the U.S. Healthcare Solutions segment, offset in part by the decrease in gross profit in the International Healthcare Solutions segment. 
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43557922/debt-strategy-in-motion-walgreens-early-cencora-share-settlement-unlocks-300-million" rel="noreferrer noopener">Walgreens Cashes In: Slashes Cencora Stake Again In Debt-Fighting Move</a>
Adjusted gross profit margin was 3.86%, an increase of 16 basis points. Adjusted operating income was $1.2 billion, a 15.3% increase, driven by an increase in the U.S. Healthcare Solutions segment, partially offset by a decrease in the International Healthcare Solutions segment. Margin was 1.58% in the fiscal 2025 second quarter, an increase of seven basis points when compared to the prior year quarter.
Guidance:&nbsp;Cencora updated its fiscal year 2025 financial guidance to reflect stronger earnings growth in the U.S. Healthcare Solutions segment and a lower contribution from the International Healthcare Solutions segment.
Cencora expects adjusted diluted EPS of $15.70-$15.95, up from prior guidance of $15.30-$15.60, compared to the consensus of $15.46.
International Healthcare Solutions segment revenue growth to be in the range of 3%-4%, down from the previous range of 4%-5%.
Adjusted consolidated operating income growth to be between 13.5%-15.5%, up from the previous range of 11.5%-13.5%.
COR Price Action: Cencora stock is up 4.71% at $304.505 at publication on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45259295/whats-going-on-with-icahn-enterprises-stock-today" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Icahn Enterprises Stock Today?</a></li>
</ul>
Photo: Shutterstock

Biotech

Earnings

Guidance

Health Care

Movers

General

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

WIIM

Cencora shares are trading higher after the company reported better-than-expected Q2 results and raised its FY25 adjusted EPS guidance.

Cencora Raises FY2025 Adj EPS Guidance from $15.30-$15.60 to $15.70-$15.95 vs $15.46 Est

Earnings Beats

Earnings Misses

Cencora Q2 Adj. EPS $4.42 Beats $4.11 Estimate, Sales $75.45B Miss $75.68B Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

UBS analyst Kevin Caliendo maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Buy and raises the price target from $298 to $335.

UBS Maintains Buy on Cencora, Raises Price Target to $335

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 12.25% on an annualized basis producing an average annual return of 25.82%. Currently, Cencora has a market capitalization of $55.42 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $311.04 today based on a price of $286.10 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745505017_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cencora Stock In The Last 5 Years

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 10 years by 9.42% on an annualized basis producing an average annual return of 19.01%. Currently, Cencora has a market capitalization of $55.54 billion. 
Buying $1000 In COR: If an investor had bought $1000 of COR stock 10 years ago, it would be worth $5,708.54 today based on a price of $286.70 for COR at the time of writing.
<h3>Cencora's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744923611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years

B of A Securities analyst Michael Funk maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Neutral and raises the price target from $270 to $285.

B of A Securities Maintains Neutral on Cencora, Raises Price Target to $285

APLE

Shares of REIT stocks are trading lower amid an overall market reversal. The sector may also be down amid a rise in the 30-year Treasury yield.

Despite Wall Street continuing to tumble at the start of the second quarter of 2025, a small group of S&amp;P 500 stocks has remained nearly untouched by the chaos triggered by <a href="https://www.benzinga.com/topic/tariffs">Donald Trump's tariff policies.</a>
Stocks that delivered standout gains in the first quarter have held their ground through the opening week of the second quarter, showing resilience as the broader market sank under pressure from tariffs and softening earnings outlooks.
The five best-performing S&amp;P 500 names in Q1 2025 — CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Cencora Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) — have seen only minimal declines in recent days, defying a sharp 10% drop in the S&amp;P 500 index fueled by mounting trade tensions and concerns over recession. 
<h3 class="wp-block-heading">Quarterly Stars In A Cloudy Market</h3>
Let's break it down:
<ul>
<li>CVS Health soared 50.9% in Q1, posting its best quarterly gain since 1975. While the S&amp;P 500 dropped 10% in the first week of April, CVS is only down 5% in Q2.</li>
<li>Philip Morris jumped 31.9% last quarter, reaching multiple record highs and logging its second-best quarter since going public in 2008. PM is down 4.8% thus far in April.</li>
<li>Newmont rode the gold wave. With gold prices up 19%, the mining giant surged 29.7%, its strongest 3-month performance since early 2020. NEM fell 7.2% in Q2, yet showed a more contained drop than the broader market.</li>
<li>Cencora, formerly AmerisourceBergen, posted a 23.8% rise, and remains up 0.2% this month, dodging the tariff-driven downturn.</li>
<li>Vertex Pharmaceuticals climbed 21% in Q1, and has stayed flat so far in Q2, showing impressive stability in biotech.</li>
</ul>
<h3 class="wp-block-heading">But How Much More Room To Run?</h3>
Despite their impressive runs, future gains may be limited. Analyst consensus shows only Newmont and CVS have potential upside of 25.8% and 13.2%, respectively, based on median price targets. 
For the others, the path forward looks far less compelling. With valuations already stretched and macroeconomic risks mounting — from renewed trade tensions to signs of weakening corporate margins — the potential for further gains could quickly evaporate if analysts begin slashing forecasts in the coming weeks.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Q1 2025 Price Change</th>
<th>YTD Price Change</th>
<th>Median Target Upside</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS Health (CVS)</td>
<td>+50.9%</td>
<td>+43.71%</td>
<td>+13.16%</td>
</tr>
<tr>
<td>Philip Morris (PM)</td>
<td>+31.9%</td>
<td>+26.02%</td>
<td>+2.86%</td>
</tr>
<tr>
<td>Newmont Corporation (NEM)</td>
<td>+29.7%</td>
<td>+21.77%</td>
<td>+25.77%</td>
</tr>
<tr>
<td>Cencora Inc. (COR)</td>
<td>+23.8%</td>
<td>+23.78%</td>
<td>+0.68%</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals (VRTX)</td>
<td>+21.0%</td>
<td>+19.20%</td>
<td>+6.66%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data as of April 7, 2025</figcaption></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44667104/speculators-raise-wagers-on-fed-emergency-rate-cuts-as-theories-of-self-induced-crash-gather-pace">Emergency Fed Rate Cut Odds Spike As Trump Says &#8216;No Inflation,&#8217; Calls for Immediate Action</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Education

Econ #s

VRTX

These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue?

The portfolio manager of AdvisorShares Focused Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWS#NYSE">CWS</a>) shares why his company's ETF is outperforming the market and many other<a href="https://www.benzinga.com/etfs"> ETFs in 2025.</a>
Beating the Market: AdvisorShares Portfolio Strategist Eddy Elfenbein highlighted the ETF he runs that beat the market in 2025 during an exclusive interview with Benzinga at Future Proof Citywide.
"We're beating the market this year," Elfenbein told Benzinga. He said it helps that the market has been "nervous" this year, pushing the nine-year-old ETF to have a five-star Morningstar rating.
"We have a lot of conservative stocks."
Elfenbein said that's where investors want to be right now and that the ETF is "at the right place at the right time."
The AdvisorShares Focused Equity ETF often holds around 25 stocks. Here are the current top five holdings and the percentage of assets they make up.
<ul>
<li>Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>): 4.8%</li>
<li>Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>): 4.7%</li>
<li>Rollins Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>): 4.5%</li>
<li>American Water Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>): 4.5%</li>
<li>Heico Crop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>): 4.4%</li>
</ul>
The portfolio manager told Benzinga that the goal of the ETF was to follow the market and create a product that puts investors first. Elfenbein said the ETF has low turnover, is tax efficient, and focuses on transparency.
Read Also: <a href="https://www.benzinga.com/news/events/25/03/44520918/andrew-pitcairn-on-multi-generational-wealth-think-in-50-year-increments">Andrew Pitcairn On Multi-Generational Wealth: &#8216;Think In 50-Year Increments&#8217;</a>
Advice for Investors: With the stock market experiencing high volatility in 2025, Elfenbein provided some advice for investors during the interview.
"The most important thing to have as an investor is a long-term focus," Elfenbein said.
The portfolio manager said the market has experienced a recent 10% pullback from the highs, which sounds bad but is less than the annual average one-year pullback of 14% each year from top to bottom.
"The key is riding those out, not letting your emotions get the best of you."
Elfenbein said it's important not to panic and head for the exits as investors because of some volatility. "Keep a level head and have good stocks that will weather the storm."
Price Action: The AdvisorShares Focused Equity ETF is up 1.8% year-to-date in 2025, beating the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which is down 2.8% year-to-date in 2025.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/events/25/03/44497987/xtrackers-etfs-offer-unique-exposure-to-hottest-themes-in-market-the-internet-era-times-two">Xtrackers ETFs Offer Unique Exposure To Hottest Themes In Market: &#8216;The Internet Era Times Two&#8217;</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
 <iframe loading="lazy" title="AdvisorShares &#x7C; Future Proof CityWide Miami 2025" width="500" height="281" src="https://www.youtube.com/embed/Hj0iYr31PoU?list=PL_xynMYmeEycXKNjPWkI98N6vKR-7s4D0" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo: Shutterstock

Exclusives

Interview

ETFs

EXCLUSIVE: AdvisorShares Portfolio Manager Says Market 'Nervous' In 2025, Encourages Investors To Have 'Long-Term Focus'

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 10 years by 7.55% on an annualized basis producing an average annual return of 18.31%. Currently, Cencora has a market capitalization of $52.20 billion. 
Buying $1000 In COR: If an investor had bought $1000 of COR stock 10 years ago, it would be worth $5,371.18 today based on a price of $269.48 for COR at the time of writing.
<h3>Cencora's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742998508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $276.5, along with a high estimate of $301.00 and a low estimate of $251.00. This current average reflects an increase of 5.64% from the previous average price target of $261.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1741986021_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Cencora is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$274.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>John Belton</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$251.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$301.00</td>
<td>$289.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cencora. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cencora compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Cencora's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cencora analyst ratings.</a>
<h2>About Cencora</h2>
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
<h3>A Deep Dive into Cencora's Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Cencora's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.78% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Cencora's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.6% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 112.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Cencora's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.72% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Cencora's debt-to-equity ratio stands notably higher than the industry average, reaching 35.96. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Cencora Stock

Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Equal-Weight and raises the price target from $251 to $274.

Wells Fargo Maintains Equal-Weight on Cencora, Raises Price Target to $274

This updated guidance reflects the Company's continued momentum in the second quarter of fiscal 2025 for its core U.S. Healthcare Solutions reportable segment and does not reflect any change in expectations for its recently completed acquisition of Retina Consultants of America.

Cencora Expects 2025 Adjusted EPS Of $15.30-$15.60, Up From The Previous Range Of $15.25-$15.55 Compared To Consensus Of $16.82-8K

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 8.2% on an annualized basis producing an average annual return of 20.8%. Currently, Cencora has a market capitalization of $47.04 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $257.27 today based on a price of $242.63 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739572215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$75.00</td>
<td>$39.4K</td>
<td>2.1K</td>
<td>8.1K</td>
</tr>
<tr>
<td>AHCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.00</td>
<td>$71.4K</td>
<td>0</td>
<td>4.7K</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$105.8K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$822.5K</td>
<td>495</td>
<td>258</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$81.1K</td>
<td>5.1K</td>
<td>217</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$270.00</td>
<td>$140.0K</td>
<td>355</td>
<td>200</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$390.00</td>
<td>$39.6K</td>
<td>484</td>
<td>151</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$610.00</td>
<td>$53.0K</td>
<td>100</td>
<td>137</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$67.50</td>
<td>$33.6K</td>
<td>1.8K</td>
<td>120</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$860.00</td>
<td>$25.3K</td>
<td>50</td>
<td>112</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 3 day(s) on February 14, 2025. This event was a transfer of 200 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $39.4K, with a price of $197.0 per contract. There were 2192 open contracts at this strike prior to today, and today 8123 contract(s) were bought and sold. 
• Regarding AHCO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>), we observe a put option sweep with bearish sentiment. It expires in 220 day(s) on September 19, 2025. Parties traded 476 contract(s) at a $10.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $71.4K, with a price of $150.0 per contract. There were 0 open contracts at this strike prior to today, and today 4752 contract(s) were bought and sold. 
• For THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we notice a call option sweep that happens to be neutral, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 300 contract(s) at a $145.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $105.8K, with a price of $355.0 per contract. There were 1108 open contracts at this strike prior to today, and today 1040 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a call option trade with bearish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $230.00 strike. The total cost received by the writing party (or parties) was $822.5K, with a price of $3290.0 per contract. There were 495 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 100 contract(s) at a $35.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $812.0 per contract. There were 5109 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option trade that happens to be bullish, expiring in 129 day(s) on June 20, 2025. This event was a transfer of 200 contract(s) at a $270.00 strike. The total cost received by the writing party (or parties) was $140.0K, with a price of $700.0 per contract. There were 355 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 99 contract(s) at a $390.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $39.6K, with a price of $400.0 per contract. There were 484 open contracts at this strike prior to today, and today 151 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on February 28, 2025. This event was a transfer of 53 contract(s) at a $610.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $53.0K, with a price of $1000.0 per contract. There were 100 open contracts at this strike prior to today, and today 137 contract(s) were bought and sold. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 65 day(s) on April 17, 2025. Parties traded 57 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $590.0 per contract. There were 1841 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bearish, expiring in 157 day(s) on July 18, 2025. This event was a transfer of 4 contract(s) at a $860.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $6340.0 per contract. There were 50 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AHCO

AMGN

MRNA

10 Health Care Stocks With Whale Alerts In Today's Session

Press Releases

Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035

Cencora Closes $1.8 Billion Senior Notes Offering

Cencora Completes Acquisition of Retina Consultants of America

Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

Harrow Partners with Cencora to Launch "Harrow Cares" Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Cencora Reports Fiscal 2025 First Quarter Results

Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

Comments

Cencora

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO